What You Should Know:
– Digital surgery pioneer Activ Surgical raises $15M in funding led by ARTIS Ventures to accelerate U.S. commercialization and European expansion efforts for its ActiveEdge platform, which enables existing surgical systems, from scopes to robots, to visualize, characterize and track tissue, in real-time beyond today’s human capability.
– ActivSight, is an easy-to-adapt, connected imaging module that seamlessly attaches to today’s laparoscopic and arthroscopic systems so outcomes can be improved immediately, providing real-time, on-demand insights, integrated into standard monitors.
– The company is aiming for FDA clearance in Q4 this year
and already has eight hospital systems in the US signed up for pilot programs.
Activ Surgical™, a Boston, MA-based digital surgery pioneer, today announced the close of a $15 million venture round led by ARTIS Ventures, a venture firm focused on pioneering investments at the intersection of life sciences and computer sciences. LRVHealth, the “Inside Healthcare” venture capital platform, joined the round, along with participation from existing investors DNS Capital, GreatPoint Ventures (GPV), Tao Capital Partners, and Rising Tide VC. To date, Activ Surgical has raised a total of $32 million.
ActivSight: Reveal Game-Changing Visual Data During Surgery
Founded in 2017, Activ Surgical is building a
hardware-agnostic platform to enable autonomous and collaborative surgery
through the integration of computer vision, artificial intelligence and
robotics. The company’s first product in the portfolio, ActivSight, is an
easy-to-adapt, connected imaging module that seamlessly attaches to today’s
laparoscopic and arthroscopic systems so outcomes can be improved immediately,
providing real-time, on demand insights, integrated into standard
monitors. The company’s second product currently in development,
ActivInsight will transform massive amounts of surgical data into intelligent,
real-time guidance for surgeons over the next 12 months.
Preventable medical errors are the third leading cause of
death after heart attack and cancer, with preventable surgical errors costing
U.S. health care $36B+ and 400k+ deaths every year. Activ Surgical’s
patent-protected surgical software platform reduces unintended and preventable
surgical complications by enhancing a surgeon’s intra-operative decision
making. In 2018, Activ Surgical completed the world’s first fully autonomous
minimally invasive robotic surgery of soft tissue.
Expansion Plans
Activ Surgical will use proceeds of the latest financing round to accelerate U.S. commercialization and European expansion efforts for itsActivEdge™ platform, which enables existing surgical systems, from scopes to robots, to visualize, characterize and track tissue, in real-time beyond today’s human capability. The company is aiming for FDA clearance in Q4 this year and already has eight hospital systems in the US signed up for pilot programs.
“Activ Surgical is poised to play a leading role in the democratization of surgical care, extending insights from experienced surgeons to surgical systems all over the globe, and ensuring world-class care for all, regardless of location,” said Todd Usen, CEO, Activ Surgical. “We welcome the guidance and support from our new and current investors and Board members as we accelerate our efforts to commercialize our first product, ActivSight. 2020 will be pivotal for our business with committed pilot projects with major hospital systems slated to launch by the end of this year.”
